Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Aequor Inc. is currently handling 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners and 2 distinct art units, which indicates a diversified approach to their current patent filings. The involvement of 2 distinct art units suggests that the company's biotechnology research spans multiple specialized categories at the patent office.
The busiest examiner for the company is JUSTICE, GINA CHIEUN YU, who oversees 1 pending office action. Since each of the 2 pending office actions is assigned to a different examiner, the applicant must manage two distinct prosecution timelines and styles. This distribution ensures that the company's progress is not entirely reliant on the decisions of a single individual across their pending matters. For a practitioner, this provides multiple opportunities to secure patent rights through different examination channels.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUSTICE, GINA CHIEUN YU | 1 | 55.6% | +8.4% |
| MURESAN, ANA Z | 1 | 75.0% | +31.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17937670 | Antimicrobial Compounds and Methods of Use | MURESAN, ANA Z | 71d overdue |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18063911 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | JUSTICE, GINA CHIEUN YU | 1617 | §103 | Non-Final OA | 99d overdue | Pending | Dec 09, 2022 |
| 17937670 | Antimicrobial Compounds and Methods of Use | MURESAN, ANA Z | 1692 | §102DP | Non-Final OA | 71d overdue | Pending | Oct 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial